biotech | KUOW News and Information

biotech

Bill Radke talks to Jon Talton, Seattle Times economics columnist, about what it would mean for the Northwest if the proposed cuts to the National Institutes of Health funding were enacted.

Biomedical research is going big-time: Megaprojects that collect vast stores of data are proliferating rapidly. But scientists' ability to make sense of all that information isn't keeping up.

This conundrum took center stage at a meeting of patient advocates, called Partnering For Cures, in New York City on Nov. 15.

On the one hand, there's an embarrassment of riches, as billions of dollars are spent on these megaprojects.

Bill Radke talks to biotech journalist Luke Timmerman about his new book, "Hood: Trailblazer of the Genomics Age." 

Bill Radke speaks with Luke Timmerman about what went wrong during Seattle-based Juno Therapeutics' clinical trial of an immunotherapy treatment for leukemia and what it might mean for the company.

Jeannie Yandel talks to Luke Timmerman of the Timmerman Report about Chris Rivera's tenure as President of the Washington Biotechnology And Biomedical Association. 

Marcie Sillman talks to Luke Timmerman, founder and editor of the Timmerman Report, about Juno Therapeutics and other biotech startups like Just Biotherapeutics that came out of the closure of Amgen's Seattle offices last year. 

The Fred Hutchison Cancer Research Center as seen from Lake Union.
Flickr Photo/sea turtle (CC-BY-NC-ND)

Marcie Sillman talks to Luke Timmerman, of the Timmerman Report, about the Fred Hutchinson's Cancer Research Center's efforts to find new ways to bring in revenue for research. 

biotech file photo
Flickr Photo/HCC PIO (CC BY-NC-ND 2.0)

Marcie Sillman talks to Luke Timmerman about the growth of a Seattle biotech company, Adaptive Biotechnologies, and what it means for the city's biotechnology industry.

Ross Reynolds talks to Seattle biotech writer Luke Timmerman about the biotech company Dendreon, which filed for bankruptcy after their prostate cancer drug failed to make a sizable profit.

Marcie Sillman talks to biotech writer Luke Timmerman about the influx of money to cancer immunotherapy companies like VentriRx, which just received $50 million to increase their research efforts.

Ross Reynolds talks to biotech reporter, Luke Timmerman, about what types of treatments biologist are studying for Ebola.

Flickr Photo/Thomas Hawk (Cc-BY-NC-ND)

Jeannie Yandel talks to Jon Talton, economic columnist for the Seattle Times and writer for the blog Rogue Columnist, about the Puget Sound's economic climate.

T-Mobile is for sale two companies, Spring and the French company, Illiad, are interested in buying it.

Also, what is the biggest danger to the Northwest's economy?

Amgen is moving out, and Expedia is moving into Seattle.
Flickr Photo/Chas Redmond (CC-BY-NC-ND)

California-based biotech firm Amgen announced on Tuesday that it would close its Seattle and Bothell campuses by 2015, resulting in the loss of 660 jobs locally. The closure is part of a company-wide layoff of an estimated 2,400 to 2,900.

Marcie Sillman talks to biotech journalist Luke Timmerman about the pharmaceutical company Merck buying the biotech company Idenix for  over $3 billion and what that means for the future of a hepatitis C treatment. Also, they discuss the latest from the American Society Of Clinical Oncology meeting.

Flickr Photo/Adam Brandejs

How is biotechnology changing our pets, our livestock and other wild things? Ross Reynolds talks with Emily Anthes, the author of "Frankenstein’s Cat: Cuddling up to Biotech’s Brave New Beasts," about how biotech will change our pets and livestock.

This interview originally aired on March 14, 2013.

Pages